오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

skinb5 pty ltd - calcium pantothenate, quantity: 500 mg (equivalent: calcium, qty 41.95 mg; equivalent: pantothenic acid, qty 458 mg); biotin, quantity: 330 microgram; nicotinamide, quantity: 125 mg; zinc gluconate, quantity: 38.29 mg (equivalent: zinc, qty 5 mg); colloidal anhydrous silica, quantity: 10.7 mg (equivalent: silicon, qty 5 mg); retinol acetate, quantity: 135.7 microgram (equivalent: vitamin a, qty 115 re); folic acid, quantity: 80 microgram; copper gluconate, quantity: 1.79 mg (equivalent: copper, qty 250 microgram) - tablet, film coated - excipient ingredients: carnauba wax; povidone; purified talc; microcrystalline cellulose; calcium hydrogen phosphate dihydrate; crospovidone; magnesium stearate; titanium dioxide; polyvinyl alcohol; macrogol 3000; lecithin - antioxidant/reduce free radicals formed in the body ; aid/assist/help/maintain healthy hair follicles ; aid/assist nail growth ; enhance/improve/promote immune defence/immunity ; maintain/support healthy immune system function ; enhance/promote body adaptation to stress ; support healthy body stress recovery ; decrease/reduce/relieve symptoms of stress ; maintain/support reproductive system health ; maintain/support healthy reproductive hormones ; relieve symptoms of acne ; decrease/reduce/relieve congested skin pores ; relieve minor skin eruptions ; decrease/reduce/relieve symptoms of acne blackheads ; helps reduce occurrence of symptoms of acne ; decrease/reduce/relieve pimples ; helps reduce occurrence of pimples ; soothe skin ; soothe/relieve skin inflammation ; decrease/reduce/relieve skin redness ; maintain/support skin health ; helps enhance/improve skin internal structure ; helps enhance/improve skin strength ; enhance/improve healing of minor skin wound/cuts/scratches/abrasions ; enhance/improve/promote skin repair/healing

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - prucalopride succinate, quantity: 2.642 mg (equivalent: prucalopride, qty 2 mg) - tablet - excipient ingredients: lactose monohydrate; polysorbate 80; iron oxide red; colloidal anhydrous silica; microcrystalline cellulose; macrogol 400; hypromellose; titanium dioxide; magnesium stearate - prucalopride is indicated for the treatment of chronic functional constipation in adults in whom laxatives fail to provide adequate relief.,? before prucalopride is considered patients must have tried at least two different types of laxatives from different classes (at the highest tolerated recommended doses) for at least six months, but have not had adequate relief from constipation.,? if treatment with prucalopride is not effective within four weeks, the benefit of continuing treatment should be reconsidered.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - prucalopride succinate, quantity: 1.321 mg (equivalent: prucalopride, qty 1 mg) - tablet - excipient ingredients: hypromellose; colloidal anhydrous silica; lactose monohydrate; polysorbate 80; microcrystalline cellulose; titanium dioxide; macrogol 400; magnesium stearate - prucalopride is indicated for the treatment of chronic functional constipation in adults in whom laxatives fail to provide adequate relief.,? before prucalopride is considered patients must have tried at least two different types of laxatives from different classes (at the highest tolerated recommended doses) for at least six months, but have not had adequate relief from constipation.,? if treatment with prucalopride is not effective within four weeks, the benefit of continuing treatment should be reconsidered.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

nutrivital pty ltd - magnesium phosphate pentahydrate, quantity: 150 mg (equivalent: magnesium, qty 30.99 mg; equivalent: phosphorus, qty 26.33 mg); pyridoxine hydrochloride, quantity: 25 mg (equivalent: pyridoxine, qty 20.56 mg); zinc amino acid chelate, quantity: 250 mg (equivalent: zinc, qty 25 mg); chromium nicotinate, quantity: 250 microgram (equivalent: chromium, qty 25 microgram); manganese amino acid chelate, quantity: 2 mg (equivalent: manganese, qty 200 microgram); retinol acetate, quantity: 0.5175 mg (equivalent: vitamin a, qty 0.45 mg) - tablet, film coated - excipient ingredients: titanium dioxide; magnesium stearate; crospovidone; carnauba wax; colloidal anhydrous silica; calcium hydrogen phosphate dihydrate; povidone; microcrystalline cellulose; macrogol 400; hypromellose; maize starch; gelatin; silicon dioxide; butylated hydroxytoluene; sucrose - antioxidant/reduce free radicals formed in the body ; helps reduce/decrease free radical damage to body cells ; maintain/support energy levels ; maintain/support healthy eye function ; maintain/support eye health ; maintain/support healthy eyesight/vision ; maintain/support body mucous membrane health ; maintain/support general health and wellbeing ; maintain/support hair health ; maintain/support nail health/strength/thickness ; maintain/support bone health ; aid/assist healthy red blood cell production ; maintain/support immune system health ; maintain/support healthy immune system function ; aid/assist/helps glucose/sugar/carbohydrate metabolism ; aid/assist/helps protein synthesis in the body ; helps prevent dietary (state vitamin/mineral/nutrient) deficiency ; aid/assist/helps metabolism of (state vitamin/mineral/nutrient) ; maintain/support cognitive function/mental function ; maintain/support nerve conduction ; maintain/support nervous system health ; maintain/support nervous system function ; maintain/support female reproductive system health ; maintain/support reproductive system health ; maintain/support healthy reproductive hormones ; maintain/support skin health ; maintain/support skin regeneration

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 29.12 mg (equivalent: tapentadol, qty 25 mg) - tablet, modified release - excipient ingredients: hypromellose; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; lactose monohydrate; purified talc; macrogol 6000; macrogol 400; titanium dioxide; iron oxide yellow; iron oxide red - palexia sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. palexia sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. palexia sr is not indicated as an as-needed (prn) analgesia.

캐나다 - 영어 - Health Canada

vita health products inc - vitamin b6; vitamin b12; folic acid; vitamin a (retinol palmitate); vitamin d3; vitamin b1 (thiamine mononitrate); vitamin b2; nicotinamide; ascorbic acid - tablet - 1mg; 3mcg; .1mg; 5000unit; 400unit; 1.5mg; 1.5mg; 15mg; 50mg - vitamin b6 1mg; vitamin b12 3mcg; folic acid .1mg; vitamin a (retinol palmitate) 5000unit; vitamin d3 400unit; vitamin b1 (thiamine mononitrate) 1.5mg; vitamin b2 1.5mg; nicotinamide 15mg; ascorbic acid 50mg - multivitamin preparations

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 291.2 mg (equivalent: tapentadol, qty 250 mg) - tablet, modified release - excipient ingredients: iron oxide red; iron oxide yellow; microcrystalline cellulose; propylene glycol; macrogol 6000; lactose monohydrate; hypromellose; magnesium stearate; purified talc; iron oxide black; titanium dioxide; colloidal anhydrous silica - palexia sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. palexia sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. palexia sr is not indicated as an as-needed (prn) analgesia.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 232.96 mg (equivalent: tapentadol, qty 200 mg) - tablet, modified release - excipient ingredients: iron oxide yellow; hypromellose; magnesium stearate; colloidal anhydrous silica; iron oxide red; lactose monohydrate; titanium dioxide; purified talc; microcrystalline cellulose; macrogol 6000; propylene glycol - palexia sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. palexia sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. palexia sr is not indicated as an as-needed (prn) analgesia.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 174.72 mg (equivalent: tapentadol, qty 150 mg) - tablet, modified release - excipient ingredients: propylene glycol; magnesium stearate; iron oxide red; hypromellose; lactose monohydrate; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; macrogol 6000; purified talc; iron oxide yellow - palexia sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. palexia sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. palexia sr is not indicated as an as-needed (prn) analgesia.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 116.48 mg (equivalent: tapentadol, qty 100 mg) - tablet, modified release - excipient ingredients: magnesium stearate; microcrystalline cellulose; purified talc; titanium dioxide; macrogol 6000; hypromellose; colloidal anhydrous silica; propylene glycol; iron oxide yellow; lactose monohydrate - palexia sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. palexia sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. palexia sr is not indicated as an as-needed (prn) analgesia.